Showing results (351-360 of 639) with videos related to
Sort By:
Pageof 64
Therapeutic Advances in Musculoskeletal Disease|November 8, 2019
Balancing benefits and risks in the era of biologicsGiovanni Adami, Kenneth G Saag, Roland D Chapurlat, et al.Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2022
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes TrialKenneth G Saag, Michael A Becker, William B White, et al.Annals of the Rheumatic Diseases|February 15, 2018
Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitorsTimothy Beukelman, Fenglong Xie, Lang Chen, et al.The Permanente Journal|July 27, 2017
Evaluation of a "Just-in-Time" Nurse Consultation on Bone Health: A Pilot Randomized Controlled TrialDouglas W Roblin, David Zelman, Sally Plummer, et al.Plos One|July 11, 2015
The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the JawNicole C Wright, Jeffrey R Curtis, Tarun Arora, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 28, 2008
Longitudinal trends in use of bone mass measurement among older americans, 1999-2005Jeffrey R Curtis, Laura Carbone, Hong Cheng, et al.Archives of Osteoporosis|March 1, 2020
Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective studyAndrew M McDonald, Eddy S Yang, Kenneth G Saag, et al.The New England Journal of Medicine|March 13, 2018
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutWilliam B White, Kenneth G Saag, Michael A Becker, et al.American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 11, 2008
Effect of racial differences on ability to afford prescription medicationsDaniel J Cobaugh, Erik Angner, Catarina I Kiefe, et al.Annals of the Rheumatic Diseases|May 29, 2021
Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritisTate M Johnson, Harlan R Sayles, Joshua F Baker, et al.Pageof 64